Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) were able to shrug off recent news of a more contagious Covid variant that popped-up in the UK. Additionally, Covid fears have done nothing to derail ongoing positive market dynamics. As long as support levels hold and market dynamics remain positive, our outlook remains bullish and we continue to view any weakness as a buying opportunity. Actionable Themes in today's report: Services, Technology, Manufacturing, and Materials.

Broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) were able to shrug off recent news of a more contagious Covid variant that popped-up in the UK. Additionally, Covid fears have done nothing to derail ongoing positive market dynamics. As long as support levels hold and market dynamics remain positive, our outlook remains bullish and we continue to view any weakness as a buying opportunity. Actionable Themes in today's report: Services, Technology, Manufacturing, and Materials.

Global Equity Strategy: Support Levels Holding; Bullish Outlook Intact

Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

Atossa Genetics is preparing to start Phase II studies of both its oral and topical endoxifen formulations in Q218. Endoxifen, an estrogen receptor (ER) antagonist, is being advanced in topical form to treat high mammographic breast density (MBD), and also as an oral drug to prevent cancer recurrence in women refractory to tamoxifen. The company plans to raise $20m in equity through a rights offering in May 2018, which we believe should fund the Phase II endoxifen trials through completion.

Atossa Genetics is preparing to start Phase II studies of both its oral and topical endoxifen formulations in Q218. Endoxifen, an estrogen receptor (ER) antagonist, is being advanced in topical form to treat high mammographic breast density (MBD), and also as an oral drug to prevent cancer recurrence in women refractory to tamoxifen. The company plans to raise $20m in equity through a rights offering in May 2018, which we believe should fund the Phase II endoxifen trials through completion.

Atossa Genetics - Endoxifen to start Phase II studies shortly

Atossa Genetics reported Phase I data on its topical endoxifen formulation and it is now developing this as a potential treatment for high mammographic breast density (MBD), which is associated with increased breast cancer risk. The firm is also developing oral endoxifen for patients refractory to tamoxifen, and its intraductal microcatheter (IDMC), combined with established cancer drug fulvestrant. After also considering the recent $5.5m equity raise (at $0.44 per share), our rNPV-derived equity valuation is $24.6m (from $9.3m previously), or $0.93 per share.

Atossa Genetics reported Phase I data on its topical endoxifen formulation and it is now developing this as a potential treatment for high mammographic breast density (MBD), which is associated with increased breast cancer risk. The firm is also developing oral endoxifen for patients refractory to tamoxifen, and its intraductal microcatheter (IDMC), combined with established cancer drug fulvestrant. After also considering the recent $5.5m equity raise (at $0.44 per share), our rNPV-derived equity valuation is $24.6m (from $9.3m previously), or $0.93 per share.

Atossa Genetics - Seeking to prevent or treat breast cancer

Atossa raised $4.4m in April 2017 in an equity raise consisting of common shares, Series A convertible preferred shares (SACPS), and warrants. We believe the proceeds should extend its cash runway into Q417 as it advances its 30-patient Phase II study on IDMC-delivering fulvestrant in patients scheduled for mastectomy or lumpectomy, and its 48-patient Phase I trial on endoxifen. We obtain an rNPV-based equity valuation of $9.3m.

Atossa raised $4.4m in April 2017 in an equity raise consisting of common shares, Series A convertible preferred shares (SACPS), and warrants. We believe the proceeds should extend its cash runway into Q417 as it advances its 30-patient Phase II study on IDMC-delivering fulvestrant in patients scheduled for mastectomy or lumpectomy, and its 48-patient Phase I trial on endoxifen. We obtain an rNPV-based equity valuation of $9.3m.

Funded into Q417, endoxifen now in Phase I

Atossa intends to raise $4.0m (gross proceeds), excluding over-allotments, in an equity offering of Class A and Class B units, consisting of 0.664m common shares (CS), 3,502 Series A convertible preferred shares (SACPS), and 5.33m common share warrants (CSW). The offering is expected to close on 3 April, subject to customary closing conditions, and we estimate that it will enable Atossa to fund its operations into Q417.

Atossa intends to raise $4.0m (gross proceeds), excluding over-allotments, in an equity offering of Class A and Class B units, consisting of 0.664m common shares (CS), 3,502 Series A convertible preferred shares (SACPS), and 5.33m common share warrants (CSW). The offering is expected to close on 3 April, subject to customary closing conditions, and we estimate that it will enable Atossa to fund its operations into Q417.

Atossa to raise $4.0m in combined class offering

United States

Atossa Therapeutics, Inc. operates as a biopharmaceutical company. The Company discovers proprietary therapeutics and delivery methods for breast cancer and other related conditions. Atossa Therapeutics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Atossa Therapeutics (ATOS US)

Global Equity Strategy: Support Levels Holding; Bullish Outlook Intact

As long as support levels hold and market dynamics remain positive, our outlook remains bullish and we continue to view any weakness as a buying...

Vermilion Research

Atossa Genetics - Endoxifen to start Phase II studies shortly

Atossa Genetics is preparing to start Phase II studies of both its oral and topical endoxifen formulations in Q218. Endoxifen, an estrogen receptor...

Edison Investment Research

Atossa Genetics - Seeking to prevent or treat breast cancer

Atossa Genetics reported Phase I data on its topical endoxifen formulation and it is now developing this as a potential treatment for high...

Edison Investment Research

Funded into Q417, endoxifen now in Phase I

Atossa raised $4.4m in April 2017 in an equity raise consisting of common shares, Series A convertible preferred shares (SACPS), and warrants. We...

Edison Investment Research

Atossa to raise $4.0m in combined class offering

Atossa intends to raise $4.0m (gross proceeds), excluding over-allotments, in an equity offering of Class A and Class B units, consisting of 0.664m...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)